IBSA Institut Biochimique SA, the multinational pharmaceutical company based in Lugano, acquired 100% of the share capital of its French distributor Laboratoires Genevrier SAS. The purchase agreement was concluded at the end of July 2021, and the French company’s name will change to IBSA Pharma SAS.
“IBSA and Laboratoires Genevrier have been collaborating successfully for more than 30 years. The acquisition is part of the Group’s strategy aimed at strengthening its commercial layout through the opening of own subsidiaries, and represents a concrete opportunity for IBSA’s continuous growth on the French market, a crucial area for our company”, stated Arturo Licenziati, President and CEO, IBSA Group.
Laboratoires Genevrier has been the distributor on the French market of pharmaceutical products manufactured by IBSA since 1987, with particular reference to the following therapeutic areas: osteoarticular, pain and inflammation, reproductive medicine, endocrinology and dermatology. IBSA Pharma SAS also will soon launch its products in the aesthetic medicine area.
Thanks to the acquisition by such a well-established international market player like IBSA, Laboratoires Genevrier achieves a chance to further develop its own business. “All Laboratoires Genevrier’s collaborators are excited to join a Group like IBSA. We are glad to have the opportunity of working in synergy with the Swiss company, sharing our mutual know-how and resources. This acquisition will allow us to improve and expand our portfolio, in order to better meet the needs of both patients and HCPs in the French market”, affirmed Fabrice Jover, General Manager at the former Laboratoires Genevrier, who will continue to work for the Company as General Manager of IBSA Pharma SAS.
